Self-Assembled Nanoconstructs Modified with Amplified Aptamers Inhibited Tumor Growth and Retinal Vascular Hyperpermeability via Vascular Endothelial Growth Factor Capturing
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jihyun | - |
dc.contributor.author | Lee, Byung Joo | - |
dc.contributor.author | Lee, Yeong Mi | - |
dc.contributor.author | Park, Hansoo | - |
dc.contributor.author | Kim, Jeong Hun | - |
dc.contributor.author | Kim, Won Jong | - |
dc.date.available | 2019-03-08T08:56:42Z | - |
dc.date.issued | 2017-05 | - |
dc.identifier.issn | 1543-8384 | - |
dc.identifier.issn | 1543-8392 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4496 | - |
dc.description.abstract | Here, nanoconstructs consisting of a DNA- amplified aptamer with a biocompatible polymer backbone for capturing target biomolecules are presented. First, the polymer-DNA nanoconstructs were prepared by hybridization of two complementary single-stranded DNAs that were each conjugated to a dextran polymer backbone. The designed polymer-DNA amplified aptamer nanoconstructs (PA-aNCs) were then prepared by utilizing polymer-DNA nanoconstructs conjugated with an aptamer (PA-NCs) using a rolling circle amplification reaction to amplify the aptamer. These PA-aNCs were successfully applied to alleviate tumor growth and vascular endothelial growth factor (VEGF)induced retinal vascular hyperpermeability in vivo through the highly effective capture of human VEGF as a target molecule. These PA-aNCs could be used as therapeutic agent for anti-VEGF therapy by efficiently capturing human VEGF. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.title | Self-Assembled Nanoconstructs Modified with Amplified Aptamers Inhibited Tumor Growth and Retinal Vascular Hyperpermeability via Vascular Endothelial Growth Factor Capturing | - |
dc.type | Article | - |
dc.identifier.doi | 10.1021/acs.molpharmaceut.6b00949 | - |
dc.identifier.bibliographicCitation | MOLECULAR PHARMACEUTICS, v.14, no.5, pp 1460 - 1468 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000400633300014 | - |
dc.identifier.scopusid | 2-s2.0-85018397688 | - |
dc.citation.endPage | 1468 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1460 | - |
dc.citation.title | MOLECULAR PHARMACEUTICS | - |
dc.citation.volume | 14 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | anti-VEGF therapy | - |
dc.subject.keywordAuthor | DNA nanoconstructs | - |
dc.subject.keywordAuthor | polymer-DNA conjugates | - |
dc.subject.keywordAuthor | antitumor therapy | - |
dc.subject.keywordAuthor | retinal vascular hyperpermeability | - |
dc.subject.keywordPlus | ANTI-ANGIOGENIC THERAPY | - |
dc.subject.keywordPlus | DIABETIC-RETINOPATHY | - |
dc.subject.keywordPlus | MACULAR DEGENERATION | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | PEGAPTANIB | - |
dc.subject.keywordPlus | TARGET | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.